These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20418508)

  • 21. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.
    Zhao P; Lee CA; Kunze KL
    Drug Metab Dispos; 2007 May; 35(5):704-12. PubMed ID: 17293381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
    Gandelman K; Zhu T; Fahmi OA; Glue P; Lian K; Obach RS; Damle B
    J Clin Pharmacol; 2011 Feb; 51(2):229-36. PubMed ID: 20371736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.
    Small DS; Ke AB; Hall SD; Mantlo N; Rotelli M; Friedrich S
    J Clin Pharmacol; 2015 Jul; 55(7):757-67. PubMed ID: 25651523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.
    Borghi C; Cicero AF
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):205-209. PubMed ID: 27852117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity.
    Li HY; Xu W; Su J; Zhang X; Hu LW; Zhang WD
    Pharmacology; 2010; 86(5-6):287-92. PubMed ID: 21042038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans.
    Dalvie D; Chen W; Zhang C; Vaz AD; Smolarek TA; Cox LM; Lin J; Obach RS
    Drug Metab Dispos; 2008 Nov; 36(11):2185-98. PubMed ID: 18694908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anacetrapib.
    Am J Cardiovasc Drugs; 2010; 10(4):267-70. PubMed ID: 20653333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.
    Krishna R; Gheyas F; Liu Y; Hagen DR; Walker B; Chawla A; Cote J; Blaustein RO; Gutstein DE
    Clin Pharmacol Ther; 2017 Nov; 102(5):832-840. PubMed ID: 28380664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interaction of diltiazem with lovastatin and pravastatin.
    Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
    Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient inhibition of cyp3a in rats by star fruit juice.
    Hidaka M; Okumura M; Ogikubo T; Kai H; Fujita K; Iwakiri T; Yamasaki K; Setoguchi N; Matsunaga N; Arimori K
    Drug Metab Dispos; 2006 Mar; 34(3):343-5. PubMed ID: 16326816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
    Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
    Chen M; Nafziger AN; Bertino JS
    Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age.
    Bianchetti G; Billy S; Ascalone V; Saivin S; Houin G; Rosenzweig P
    Int J Clin Pharmacol Ther; 1996 May; 34(5):195-201. PubMed ID: 8738855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.